Hansoh Biomedical R&d Company

This study tests two experimental drugs, HS-20093 and HRS-5041, together in men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to find the safest dose and understand side effects. About 63 participants will take part in this ear…

This study tests a new drug called HS-20089 against standard chemotherapy in people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 468 women aged 18 and older will be randomly assigned to receive either H…

This study tests a new drug combination (HS-20110) in people with advanced colorectal cancer that has not responded to standard treatments. The goal is to find the safest dose and see if it can shrink tumors. About 500 adults will take part in this early-phase trial across multip…

This early-stage trial tests a new drug called HS-20110 in 475 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and see if the drug can shrink tumors. Researchers will also monitor side effects and how long …

This early-stage trial tests a drug called HS-20093 in 40 adults with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The drug is designed to attach to a protein on cancer cells and deliver a toxic payload directly to them. The …

This early-stage study tests a new drug called HS-20122 in about 1,050 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. This is a first-in-human trial, so the drug's effectivenes…

This study looks at how the antifungal drug itraconazole changes the way the body processes HS-20093, an experimental cancer treatment. It involves 18 adults with advanced solid tumors who have not responded to or cannot tolerate standard therapies. The goal is to measure drug le…